Frontiers in Pharmacology | Inflammation Pharmacology

Original Research

Published on 15 Jan 2024

Valsartan attenuates LPS-induced ALI by modulating NF-κB and MAPK pathways

in Inflammation Pharmacology

Mi Zhou
Ling Meng
Qinke He
Chunguang Ren
Changyi Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1321095

8,481 views
16 citations

Correction

Published on 11 Jan 2024

Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

in Inflammation Pharmacology

Can G. Leineweber
Miriam Rabehl
Anne Pietzner
Nadine Rohwer
Michael Rothe
Maciej Pech
Bruno Sangro
Rohini Sharma
Chris Verslype
Bristi Basu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1354581

1,384 views

Original Research

Published on 09 Jan 2024

Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system

in Inflammation Pharmacology

Chunyan Wei
Wanhong Yin
Tingting Hu
Jingyi Zhang
Huifang Dan
Bin Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1323240

3,393 views
3 citations

Review

Published on 08 Jan 2024

Pterostilbene in the treatment of inflammatory and oncological diseases

in Inflammation Pharmacology

Peijun Liu
Weihua Tang
Kali Xiang
Guangcai Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1323377

17,525 views
27 citations

Mini Review

Published on 03 Jan 2024

Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy

in Inflammation Pharmacology

Xiao-Huan Wei
Yuan-Yuan Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1326281

8,243 views
13 citations

Editorial

Published on 14 Dec 2023

Editorial: Implication of oxidative, inflammatory, apoptotic and autophagy pathways in colitis

in Inflammation Pharmacology

Hanan M. Hassan
Mohamed M. Salama

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1326176

1,543 views

Original Research

Published on 07 Dec 2023

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

in Inflammation Pharmacology

Huqun Li
Chongshu Wang
Aiping Deng
Cuilian Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1280490

3,615 views
6 citations

Systematic Review

Published on 07 Dec 2023

Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials

in Inflammation Pharmacology

Liuting Zeng
Qi He
Ying Deng
Yuwei Li
Junpeng Chen
Kailin Yang
Yanfang Luo
Anqi Ge
Xiaofei Zhu
Zhiyong Long

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1189142

6,134 views
7 citations

Editorial

Published on 06 Dec 2023

Editorial: Lipidomics of oxylipins in biological systems

in Inflammation Pharmacology

Paola Patrignani
Nils Helge Schebb
Oliver Werz
Dieter Steinhilber

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1342596

2,360 views

Original Research

Published on 29 Nov 2023

ACT001 improved cardiovascular function in septic mice by inhibiting the production of proinflammatory cytokines and the expression of JAK-STAT signaling pathway

in Inflammation Pharmacology

Zhen Peng
Xiaolong Lv
Xintong Wang
Ting Shang
Jing Chang
Khalid Salahdiin
Yue Guo
Zhisen Zhang
Ru Shen
Ming Lyu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1265177

4,790 views
5 citations

Original Research

Published on 20 Nov 2023

IL-37 counteracts inflammatory injury in the temporomandibular joint via the intracellular pathway

in Inflammation Pharmacology

Jun Li
Sisi Peng
Ying Yan
Shan Yan
Xin Cao
Yong Li
Luying Zhu
Jie Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1250216

2,603 views

Review

Published on 16 Nov 2023

Current and promising therapies based on the pathogenesis of Graves’ ophthalmopathy

in Inflammation Pharmacology

Xin Zhang
Qixiang Zhao
Bei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1217253

7,237 views
10 citations

Review

Published on 15 Nov 2023

Immunomodulatory roles of metalloproteinases in rheumatoid arthritis

in Inflammation Pharmacology

Yanqin Bian
Zheng Xiang
Yaofeng Wang
Qing Ren
Guoming Chen
Bei Xiang
Jianye Wang
Chengbo Zhang
Shaoqiang Pei
Shicheng Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1285455

9,653 views
31 citations

Original Research

Published on 10 Nov 2023

Suppression of inflammation-induced lung cancer cells proliferation and metastasis by exiguaflavanone A and exiguaflavanone B from Sophora exigua root extract through NLRP3 inflammasome pathway inhibition

in Inflammation Pharmacology

Punnida Arjsri
Kamonwan Srisawad
Warathit Semmarath
Sonthaya Umsumarng
Lapamas Rueankham
Aroonchai Saiai
Methee Rungrojsakul
Trinnakorn Katekunlaphan
Songyot Anuchapreeda
Pornngarm Dejkriengkraikul

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1243727

3,758 views
8 citations

Mini Review

Published on 06 Nov 2023

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review

in Inflammation Pharmacology

Qiang Cao
Xinyan Wu
Qi Zhang
Junling Gong
Yuquan Chen
Yanwei You
Jun Shen
Yi Qiang
Guangzhu Cao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1291920

9,437 views
24 citations

Mini Review

Published on 06 Nov 2023

Role of signaling lymphocytic activation molecule family of receptors in the pathogenesis of rheumatoid arthritis: insights and application

in Inflammation Pharmacology

Yixin Zheng
Jianan Zhao
Mi Zhou
Kai Wei
Ping Jiang
Lingxia Xu
Cen Chang
Yu Shan
Linshuai Xu
Yiming Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1306584

4,510 views
14 citations